School of Biological Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, 4240 Fair Street, Lincoln, NE 68503, USA.
Mayo Vaccine Research Group, General Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA.
Viruses. 2020 Oct 20;12(10):1186. doi: 10.3390/v12101186.
On average, there are 3-5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains. Therefore, the development of a universal influenza vaccine is a top priority for the NIH. Here, we report a comprehensive summary of all universal influenza vaccines that were tested in clinical trials during the 2010-2019 decade. Of the 1597 studies found, 69 eligible clinical trials, which investigated 27 vaccines, were included in this review. Information from each trial was compiled for vaccine target, vaccine platform, adjuvant inclusion, clinical trial phase, and results. As we look forward, there are currently three vaccines in phase III clinical trials which could provide significant improvement over seasonal influenza vaccines. This systematic review of universal influenza vaccine clinical trials during the 2010-2019 decade provides an update on the progress towards an improved influenza vaccine.
平均而言，每年全球有 300 万至 500 万例严重的流感病毒感染病例。季节性流感疫苗对不同的流感株提供的保护作用有限。因此，开发通用流感疫苗是 NIH 的首要任务。在这里，我们全面总结了 2010 年至 2019 年期间在临床试验中测试的所有通用流感疫苗。在发现的 1597 项研究中，有 69 项符合条件的临床试验，共涉及 27 种疫苗，被纳入本综述。从每个试验中收集了有关疫苗靶标、疫苗平台、佐剂包含、临床试验阶段和结果的信息。展望未来，目前有三种疫苗处于 III 期临床试验阶段，它们可能比季节性流感疫苗有显著的改进。本综述对 2010 年至 2019 年期间通用流感疫苗临床试验进行了系统回顾，为改进流感疫苗的进展提供了最新信息。
